Acute Myeloid Leukemia (AML) clinical trials
Showing 301–350 of 392 active trials. Describe your situation to see which ones you may be eligible for.
- Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
- Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Caris Chromoseq Data Collection
- A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- A Long Term Follow-up Study of TScan TCR-T Products
- A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
- Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
- Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
- HPC Offered for PRESERVE Expansion
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Longitudinal Studies of Patient With FPDMM
- Umbilical Cord Blood Transplantation From Unrelated Donors
- Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
- Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
- Novel Digital Application for Patients With Acute Leukemia
- Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
- Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
- Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Home Blood Transfusions
- Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
- A Telehealth Advance Care Planning Intervention
- eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
- GM-CSF With Post-Transplant Cyclophosphamide
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
- Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
- BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
- A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
- Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.